Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Large Decline in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the target of a large drop in short interest in May. As of May 29th, there was short interest totaling 17,200 shares, a drop of 71.4% from the May 14th total of 60,118 shares. Based on an average trading volume of 132,680 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics as of its most recent SEC filing. 7.06% of the stock is owned by institutional investors.

Indaptus Therapeutics Stock Up 44.5%

NASDAQ:INDP traded up $1.09 during mid-day trading on Thursday, reaching $3.54. 3,272,764 shares of the stock were exchanged, compared to its average volume of 560,439. The company has a 50 day simple moving average of $2.19 and a 200-day simple moving average of $2.21. The stock has a market capitalization of $400.98 million, a P/E ratio of -0.23 and a beta of 1.25. Indaptus Therapeutics has a 1 year low of $0.92 and a 1 year high of $19.91.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.87) by $1.64.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.